Second-Generation Anti-VEGFs in Age-Related Macular Degeneration

According to Dr. Carl Regillo, Chief of the Wills Eye Retina Service, the cumulative evidence and experience in real-world settings has highlighted an unmet need for more durable VEGF inhibition, a treatment gap that appears to have been filled, at least in part, by the introduction of the so-called second-generation anti-VEGF inhibitors aflibercept 8 mg (Eylea HD, Regeneron) and faricimab-svoa (Vabysmo, Genentech.

Read the article in Glaucoma Today.